Company
Brisbane, QLD
Every investor coverage indicates participated in a round Xenome raised.
Companies Xenome acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Julie Cherrington | Chair (former) | GBS Ventures (Tue 17 Jan 2012), GBS Ventures (Tue 11 Aug 2009) |
| Jim Hazel | Chairman of the Board | GBS Ventures (Tue 25 May 2010), GBS Ventures (Tue 11 Aug 2009) |
Stories naming Xenome. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A January 2012 post on GBS Ventures' news page announces Julie Cherrington as the new board chair of Xenome, tasked with steering the company through a pivotal stage; details sit in an attached document.
A brief post on the venture firm's news page records that Xenome has completed an eight-million-dollar financing, referring readers to a downloadable file for particulars.
Xenome appointed Dr Julie Cherrington, president of San Diego biopharmaceutical Phenomix and a Progen board member, as an independent director of the drug developer, effective 1 August 2009.